Company Overview and News


Add BLFS
to your dashboard

Headline News

BioLife Solutions: Third-Quarter Results Point To Continued Upside

2017-11-14 seekingalpha
Encouraging guidance bodes well and I wouldn't be surprised for 2018 revenue projections to be raised again in the future. (32-0)

BioLife Solutions' (BLFS) CEO Mike Rice on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good day, ladies and gentlemen, and welcome to the Third Quarter 2017 BioLife Solutions Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (40-0)

BioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial of AlloJoin™

2017-09-19 prnewswire
BOTHELL, Wash., Sept. 19, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife"), announced that Cellular Biomedicine Group (NASDAQ: CBMG), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases ("CBMG"), has validated BioLife's proprietary CryoStor freeze media for use in CBMG's planned US Phase I clinical trial of AlloJoin, an off the shelf allogeneic stem cell therapy for knee osteoarthritis. (35-0)

Matrix Capital Management Company, LP discloses 12.90% ownership in ADAP / Adaptimmune Therapeutics plc - Fintel.io

2017-09-11 fintel.io
September 11, 2017 - Matrix Capital Management Company, LP has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 72,261,066 shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP). This represents 12.9 percent ownership of the company. (0-3)

BioLife Is On The Rise After Earnings - Here's Why

2017-08-11 seekingalpha
Subscribers to ALR's Trading Ideas received early access to this article featuring BioLife Solutions (BLFS), and much more.

BioLife Solutions' (BLFS) CEO Michael Rice on Q2 2017 Results - Earnings Call Transcript

2017-08-11 seekingalpha
Good day, ladies and gentlemen, and welcome to the Q2 2017 BioLife Solutions Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference is being recorded.

BioLife Solutions Announces Second Quarter 2017 Financial Results

2017-08-10 prnewswire
29% Year Over Year Revenue Growth Conference Call and Webcast Today at 4:30 PM Eastern Time

BioLife Earnings: Here's What To Expect

2017-08-09 seekingalpha
Subscribers to ALR's Trading Ideas received early access to this article featuring BLFS, and much more.

BioLife Solutions to Report Second Quarter 2017 Financial Results and Provide Business Update on August 10, 2017

2017-08-03 prnewswire
BOTHELL, Wash., Aug. 3, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's second quarter 2017 financial results will be released after market close on Thursday, August 10, 2017, and that the Company will host a conference call and live webcast at 1:30 p.

Featured Company News – BioLife Solutions Executes Supply Agreement with Celyad for CryoStor(R) Use in Natural Killer Receptor based T-Cell (NKR-T) Platform

2017-08-02 accesswire
LONDON, UK / ACCESSWIRE / August 2, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=BLFS. The Company, which is a prominent developer, manufacturer, and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced on July 31, 2017, that it has entered into a long term supply agreement with NASDAQ-listed Celyad, a leading player of CAR-T cell therapies.

Could BioLife Be Headed To $5?

2017-08-01 seekingalpha
In this article, we revisit BioLife Solutions (BLFS). We are actively considering a long position in BLFS after exiting several short-term positions late last year for a large profit. BLFS operates in the life sciences industry, has a $45.5 million market cap, and is listed on the Nasdaq. We initially wrote a bullish PRO article on the company when BLFS traded at approximately $1.86 per share, and we have continued to write bullish articles on BLFS ever since.

Global Dementia and Movement Disorder Treatment Market 2017-2021: Dominated by MAO Inhibitors, AChE Inhibitors & Glutamate Inhibitors

2017-07-26 prnewswire
The "Global Dementia and Movement Disorder Treatment Market 2017-2021" report has been added to Research and Markets' offering.

Top Analyst Upgrades and Downgrades: BHP Billiton, Capital One, Chemours, Constellation Brands, Novartis, Teradyne, Weyerhaeuser and More

2017-07-05 247wallst
Stocks were indicated to open marginally higher on Wednesday after a day off and after a strong Dow rally on Monday. Nasdaq stocks were also indicated higher on Wednesday despite falling on Monday. Even though this bull market is now well over eight years old, equity investors keep finding myriad new reasons to buy any major pullback or sell-off. Investors are also continuing to search for new investing and trading ideas.

BioLife Solutions Executes Supply Agreement with Adaptimmune for CryoStor® Use in SPEAR T-Cell Platform

2017-06-14 prnewswire
BOTHELL, Wash., June 14, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that it has entered into a supply agreement with NASDAQ-listed Adaptimmune Therapeutics plc.

CUSIP: 09062W204